Lumida
/DAWN
⌘K
Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

DAWN
$21.53USD+0.19%+0.04 today

MARKET CAP

2.2B

P/E (TTM)

FWD P/E

DAY RANGE

$21 – $22

52W RANGE

$6
$22

AI Summary

Stalk
StalkMedium

DAWN remains in Stage 2 Advancing with robust parabolic trend acceleration but is highly extended above steeply rising EMAs without clear pullback, making immediate execution unfavorable. Under a speculative strategy requiring distinct asymmetry, execution is deferred until a constructive retracement into rising EMA or support zones emerges. Medium-term bias stays bullish, but timing awaits a defined pullback for a higher probability entry.

  • Ojemda net revenue $155.4M (+172% YoY) in 2025
  • Prescriptions >4,600 (+180% YoY), up 15% QoQ
  • Sustaining adoption may falter due to entrenched therapy use
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$131.2M$158.2M
YoY %+20.6%
P / Sales9.0x6.1x
EV / Sales8.7x5.3x
Gross Profit, Adj.$125.9M$141.0M
YoY %+12.0%
Margin %96.0%89.1%
EV / Gross Profit9.0x5.9x
EBITDA, Adj.$-215.7M$-124.3M
YoY %-4.7%+42.4%
Margin %-164.5%-78.6%
EV / EBITDA-5.3x-6.7x
EBIT$-217.3M$-127.8M
YoY %-5.4%+41.2%
Margin %-165.7%-80.8%
EV / EBIT-5.2x-6.5x
Net Income$-95.5M$-107.3M
YoY %+49.5%-12.4%
Net Margin-72.8%-67.8%
EPS (GAAP)-$1.02-$1.04
YoY %+57.0%-2.0%